JP2017521445A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017521445A5 JP2017521445A5 JP2017502240A JP2017502240A JP2017521445A5 JP 2017521445 A5 JP2017521445 A5 JP 2017521445A5 JP 2017502240 A JP2017502240 A JP 2017502240A JP 2017502240 A JP2017502240 A JP 2017502240A JP 2017521445 A5 JP2017521445 A5 JP 2017521445A5
- Authority
- JP
- Japan
- Prior art keywords
- galectin
- pharmaceutical composition
- mammal
- antagonist
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 102100031351 Galectin-9 Human genes 0.000 claims 16
- 101710121810 Galectin-9 Proteins 0.000 claims 16
- 241000124008 Mammalia Species 0.000 claims 13
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 10
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 10
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 10
- 239000005557 antagonist Substances 0.000 claims 10
- 239000003112 inhibitor Substances 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 6
- 230000036039 immunity Effects 0.000 claims 6
- 229940122789 Galectin-9 agonist Drugs 0.000 claims 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000002708 enhancing effect Effects 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 229940121958 Galectin-9 antagonist Drugs 0.000 claims 1
- 102000007563 Galectins Human genes 0.000 claims 1
- 108010046569 Galectins Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000006054 immunological memory Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021068435A JP2021105055A (ja) | 2014-07-14 | 2021-04-14 | ガレクチン免疫療法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014902709 | 2014-07-14 | ||
| AU2014902709A AU2014902709A0 (en) | 2014-07-14 | Galectin immunotherapy | |
| AU2014904466A AU2014904466A0 (en) | 2014-11-06 | Galectin immunotherapy | |
| AU2014904466 | 2014-11-06 | ||
| PCT/AU2015/050393 WO2016008005A1 (en) | 2014-07-14 | 2015-07-14 | Galectin immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021068435A Division JP2021105055A (ja) | 2014-07-14 | 2021-04-14 | ガレクチン免疫療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017521445A JP2017521445A (ja) | 2017-08-03 |
| JP2017521445A5 true JP2017521445A5 (enExample) | 2018-08-16 |
Family
ID=55077738
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017502240A Pending JP2017521445A (ja) | 2014-07-14 | 2015-07-14 | ガレクチン免疫療法 |
| JP2021068435A Pending JP2021105055A (ja) | 2014-07-14 | 2021-04-14 | ガレクチン免疫療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021068435A Pending JP2021105055A (ja) | 2014-07-14 | 2021-04-14 | ガレクチン免疫療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20170152317A1 (enExample) |
| EP (1) | EP3169349A4 (enExample) |
| JP (2) | JP2017521445A (enExample) |
| KR (1) | KR20170040796A (enExample) |
| CN (1) | CN106999548A (enExample) |
| AU (1) | AU2015291783B2 (enExample) |
| BR (1) | BR112017000667A2 (enExample) |
| CA (1) | CA2954678A1 (enExample) |
| SG (1) | SG11201700281SA (enExample) |
| WO (1) | WO2016008005A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3490568A4 (en) * | 2016-07-29 | 2020-04-15 | New York University | TREATING SOLID TUMORS BY TARGETING DECTIN-1 SIGNALING |
| JP2019528689A (ja) * | 2016-08-11 | 2019-10-17 | ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ | 免疫調節化合物 |
| EP3497448B1 (en) * | 2016-08-11 | 2023-11-15 | The Council of the Queensland Institute of Medical Research | Immune status biomarkers and uses therefor |
| SG11202003652QA (en) | 2017-10-27 | 2020-05-28 | Univ New York | Anti-galectin-9 antibodies and uses thereof |
| CN114025797A (zh) * | 2019-05-31 | 2022-02-08 | 昆士兰医学研究所理事会 | 抗Gal9免疫抑制性结合分子 |
| JP2022534624A (ja) * | 2019-05-31 | 2022-08-02 | ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ | 活性化抗ｇａｌ９結合分子 |
| JP7703513B2 (ja) * | 2019-08-01 | 2025-07-07 | ニューヨーク・ユニバーシティ | 抗ガレクチン９抗体と化学療法剤の組合せがん治療 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7030219B2 (en) * | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
| CN1688695B (zh) * | 2000-04-28 | 2011-05-11 | 约翰霍普金斯大学 | 新的树突状细胞共刺激分子 |
| EP1320599A2 (en) * | 2000-06-28 | 2003-06-25 | Genetics Institute, LLC | Pd-l2 molecules: pd-1 ligands and uses therefor |
| JP2003189874A (ja) * | 2001-12-28 | 2003-07-08 | Galpharma Co Ltd | ガレクチン−９活性制御剤 |
| US20060134119A1 (en) * | 2003-01-24 | 2006-06-22 | Mitsuomi Hirashima | Drugs containing galectin 9 |
| EP1619203A1 (en) * | 2003-04-28 | 2006-01-25 | Galpharma Co., Ltd. | Galectin 9-inducing factor |
| EP2468765B1 (en) * | 2006-03-03 | 2015-04-22 | ONO Pharmaceutical Co., Ltd. | Tetramer of extracellular domain of PD-L1 |
| JP2011514895A (ja) * | 2008-02-29 | 2011-05-12 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 精製免疫グロブリン融合タンパク質およびその精製方法 |
| JP2012500652A (ja) * | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | 標的化共刺激ポリペプチドおよび癌を処置するための使用方法 |
| WO2010084999A1 (en) * | 2009-01-26 | 2010-07-29 | Protegene, Inc. | Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases |
| US20130017199A1 (en) * | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| JPWO2012077811A1 (ja) * | 2010-12-09 | 2014-05-22 | 株式会社ガルファーマ | ガレクチン９を分泌する細胞、その製造方法及びその用途 |
| WO2012177788A1 (en) * | 2011-06-20 | 2012-12-27 | La Jolla Institute For Allergy And Immunology | Modulators of 4-1bb and immune responses |
-
2015
- 2015-07-14 WO PCT/AU2015/050393 patent/WO2016008005A1/en not_active Ceased
- 2015-07-14 CA CA2954678A patent/CA2954678A1/en not_active Abandoned
- 2015-07-14 BR BR112017000667-7A patent/BR112017000667A2/en not_active IP Right Cessation
- 2015-07-14 US US15/325,789 patent/US20170152317A1/en not_active Abandoned
- 2015-07-14 JP JP2017502240A patent/JP2017521445A/ja active Pending
- 2015-07-14 CN CN201580048553.7A patent/CN106999548A/zh active Pending
- 2015-07-14 AU AU2015291783A patent/AU2015291783B2/en not_active Ceased
- 2015-07-14 KR KR1020177003994A patent/KR20170040796A/ko not_active Withdrawn
- 2015-07-14 EP EP15822359.4A patent/EP3169349A4/en not_active Withdrawn
- 2015-07-14 SG SG11201700281SA patent/SG11201700281SA/en unknown
-
2018
- 2018-12-19 US US16/226,302 patent/US20190127474A1/en not_active Abandoned
-
2021
- 2021-04-14 JP JP2021068435A patent/JP2021105055A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
| Sternberg et al. | A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update | |
| CY1120941T1 (el) | Παραγωγα φαινυλοτριαζολιου υποκατεστημενα με υδροξυαλκυλιο και χρησεις αυτων | |
| JP2011184466A5 (enExample) | ||
| JP2016533366A5 (enExample) | ||
| JP2016530268A5 (enExample) | ||
| EA201501032A1 (ru) | Фармацевтическая композиция, способы лечения и ее применения | |
| JP2016513640A5 (enExample) | ||
| PH12017502358A1 (en) | Factor xi antibodies and methods of use | |
| MX2020001980A (es) | Antagonistas de celulas t con dominios de inmunoglobulina y mucina 3 (tim-3) para el tratamiento y diagnostico de canceres. | |
| EA201790330A1 (ru) | Белки, связывающиеся с bcma (cd269/tnfrsf17) | |
| EA201491011A1 (ru) | Способы лечения с помощью ингибитора гамма-интерферона | |
| JP2017226690A5 (enExample) | ||
| JP2017516775A5 (enExample) | ||
| UA116871C2 (uk) | СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII | |
| EA201590523A1 (ru) | Il-18-связывающие молекулы | |
| MX2023002554A (es) | Anticuerpos anti-il-1r3 humanizados. | |
| EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
| EA201291067A1 (ru) | Гуманизированные антигенсвязывающие белки к миостатину | |
| ATE516814T1 (de) | 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese | |
| UA115439C2 (uk) | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн | |
| JP2019510739A5 (enExample) | ||
| CY1115349T1 (el) | Εξανθρωπισμενα αντι cxcr4 αντισωματα για τη θεραπεια καρκινου | |
| JP2016530267A5 (enExample) | ||
| MX385589B (es) | RÉGIMEN DE DOSIFICACIÓN PARA ANTAGONISTAS DE MAdCAM. |